incrementalTreatment update
Lenalidomide plus dexamethasone long-term data confirm durable responses
POEMS Syndrome →Summary
Extended follow-up of lenalidomide-dexamethasone treated patients shows 3-year OS of 90% and 3-year PFS of 75% with neurologic response rates of 95%. Low-dose lenalidomide (10-25 mg) combined with dexamethasone appears well tolerated with no treatment-related deaths reported in the prospective He et al. 2018 study.
More from POEMS Syndrome
significantTreatment update
Daratumumab emerging as treatment option for relapsed POEMS
significantDiagnostic advance
VEGF validated as reliable response biomarker across treatment modalities
incrementalTreatment update
Improved transplant outcomes in the modern era
significantNew research
Single-cell analysis reframes VEGF pathogenesis: plasma cells produce IL-6, not VEGF
ID: poems-syndrome-update-3Type: treatment_updateImpact: incremental